24 Aug Xcell Biosciences
Brian Feth, CEO
Oct. 6 | 11:00 AM | FLW Ballroom F
San Francisco, CA
(Private)
Xcellbio is a venture-backed (Viking, Casdin, HBM, Labcorp) San Francisco-based cell therapy technology company with a novel GMP manufacturing platform designed to enhance metabolic fitness leading to more persistent and potent cell therapies. The Company’s proprietary approach to modifying immunometabolism, protected by over a dozen patent families, drives improvements in cell therapy potency and enable AI-driven optimization of therapeutic products during manufacturing. The Company offers platforms for both small- and large-scale process development and manufacturing of immune cell therapies, as well as platforms to assess the functional potency of cell therapies. The core Avatar technology was approved for clinical use in 2023 and is used for every patient that receives one of the branded gene therapies for sickle cell anemia. In addition, the Company, along with its partners, is advancing several cell therapies to IND filings with plans for first-in-human use in early 2026.
